PAMS

Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder

Retrieved on: 
Tuesday, July 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, GAD, University, Dell Medical School, Benzodiazepine, PAM, University of Texas at Austin, Doctor of Philosophy, Acquisition, MD, Patient, Risk, Psychiatry, Behavioural sciences, PAMS, Rest, Safety, Pharmaceutical industry, Engrailed

Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).

Key Points: 
  • Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).
  • ENX-102 is an investigational, highly selective GABA-A α2,3,5 positive allosteric modulator (PAM) and antagonist at α1-containing GABA-A channels.
  • “Translational and phase 1 clinical data indicate central target engagement with a highly differentiated safety and tolerability profile for ENX-102 vs. non-selective GABA-A PAMs such as benzodiazepines.
  • These data support further evaluation of ENX-102 for efficacy in generalized anxiety disorder,” said Kimberly Vanover, PhD, chief scientific officer of Engrail.

Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update

Retrieved on: 
Thursday, April 27, 2023
Vamorolone, Prescription Drug User Fee Act, Duchenne muscular dystrophy, Civil service commission, Education, Vitamin D deficiency, Health care, Glucocorticoid, European Medicines Agency, NDA, LR, European Directive on Traditional Herbal Medicinal Products, Biomarker, BMD, Committee, EMA, Vomiting, Depression, Prednisone, Publication, DMD, Vertebral compression fracture, PAMS, Patient, Annual report, Leber's hereditary optic neuropathy, European Commission, CEST, Syndrome, PDUFA, Committee for Medicinal Products for Human Use, MAA, FDA, LHON, CHF, EC, Safety, News, Bone fracture, MHRA, CHMP, BST, Cryptocurrency, Pharmaceutical industry, Medical device, Dietary supplement, Dentistry, EU, Idebenone

As permitted by SIX Exchange Regulation, the Company will publish the full 2022 Annual Report by the end of May.

Key Points: 
  • As permitted by SIX Exchange Regulation, the Company will publish the full 2022 Annual Report by the end of May.
  • The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, vomiting and vitamin D deficiency.
  • SIX Exchange Regulation has permitted Santhera to publish its 2022 Annual Report by May 31, 2023, at the latest.
  • The Company plans to publish its audited 2022 Annual Report during May 2023.

Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

Retrieved on: 
Tuesday, April 25, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, DNA, Therapy, PAM, HTT, Allele, Gene editing, Life, Mutation, Protospacer adjacent motif, Brain, Rgn, RNA, AAV, Huntingtin, CAG, Indel, Genome, Patient, Collection, SNP, Liver, Ecosystem, R, PAMS, Gene, Conference, Vaccine

Life Edit’s presentations underscore the ability of its gene editing platform to selectively target disease-associated genetic factors to treat life-threatening diseases.

Key Points: 
  • Life Edit’s presentations underscore the ability of its gene editing platform to selectively target disease-associated genetic factors to treat life-threatening diseases.
  • Wild-type HTT protein is purported to be physiologically critical, hence selective editing of the mutant HTT (mutHTT) protein is necessary for therapeutic benefit.
  • AAV5-delivered Life Edit gene editing systems enabling allele-specific targeting of mutant HTT demonstrated dose-response reductions in striatal mutHTT protein with clinically meaningful reductions of >50% observed.
  • Our recent technology advancements will help us to further power the Life Edit gene editing platform, support our partners, and selectively build out our pipeline of innovative therapeutic candidates."

StrongDM Announces the First Dynamic Access Management Platform

Retrieved on: 
Tuesday, March 28, 2023
Data Management, Security, Apps, Applications, Technology, Other Technology, Software, Networks, Database, GCP, CISO, Research, Oracle, National Technical Reports Library, Organization, Amazon, DB2, Friction, Risk, Zero trust security model, Snowflake, MongoDB, PAMS, DAM, Natural language, Computer data storage, Nursing, Online shopping, Audit, Kubernetes, StrongDM, Verizon Communications, Elasticsearch

StrongDM , the dynamic access company, today announced the launch of the StrongDM™ Dynamic Access Management (DAM) platform.

Key Points: 
  • StrongDM , the dynamic access company, today announced the launch of the StrongDM™ Dynamic Access Management (DAM) platform.
  • StrongDM Dynamic Access Management fundamentally reimagines secure infrastructure access by integrating with the entire tech stack from legacy on-prem Oracle and DB2 to cloud-hosted Snowflake and Kubernetes.
  • This extends secure access to all technical staff while eliminating friction and improving ease of access and access management for everyone from developers to the C-Suite.
  • “Better Mortgage uses StrongDM to implement Just-In-Time dynamic access, eliminating credentials and reducing risk by enforcing least privileged access."

Bionomics’ Half-Year Report

Retrieved on: 
Thursday, February 23, 2023
MSD, Safety, American depositary receipt, Post-traumatic stress disorder, SUDS, BNC210, Deficit spending, Subjective units of distress scale, Merck, Social anxiety disorder, Bionomics, ASX, PAMS, Partnership, SAD, Merck & Co., United Kingdom, Research, Patient, PTSD, MDMA, CNS, Non-executive director, Public, BNO, ADS, Data, Pharmaceutical industry

ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022.

Key Points: 
  • ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022.
  • The Company recently completed its Phase 2 PREVAIL Study to evaluate BNC210 for the acute treatment of Social Anxiety Disorder (SAD).
  • The PREVAIL Study completed recruitment, and topline data were reported on 19 December 2022.
  • The Company is continuing its analysis of the PREVAIL dataset and is assessing the next steps for the development of BNC210 in SAD.

Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

Retrieved on: 
Thursday, December 8, 2022
Psychosis, Family, ADX71149, American depositary receipt, Chronic cough, Spasticity, Janssen, Depression, Quality of life, GPCR, Janssen Pharmaceuticals, Drug discovery, Protein, Clinical trial, Glutamate receptor, LON, Glutamate (neurotransmitter), Baclofen, NAM, Secondary research, Pain, PAMS, Epilepsy, LR, SIX Swiss Exchange, Allosteric regulation, GABAB, Research, IND, Glutamic acid, Therapy, GABA, Spinal cord injury, SIX, PAM, Pharmaceutical industry, Indivior

As part of the amended agreement, Indivior will pay Addex an additional USD 1 million to cover additional research activities during this extended period.

Key Points: 
  • As part of the amended agreement, Indivior will pay Addex an additional USD 1 million to cover additional research activities during this extended period.
  • Addex retains exclusive rights to develop its own independent GABAB PAM program and is advancing compounds in Charcot-Marie-Tooth type 1A neuropathy (CMT1A), chronic cough and pain.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

WALLIX STRENGTHENS ITS CHANNEL FIRST STRATEGY AND LAUNCHES A PROGRAM DEDICATED TO MSPs (MANAGE SERVICE PROVIDERS)

Retrieved on: 
Friday, December 16, 2022
Knowledge, Heart, PAMS, PCI DSS, GSIS, PAM, Ecosystem, Service provider, Channel, GDPR, Environment, Practice, School, Research, PCI, Privacy, Frost, OT, Digital, DACH, Operational technology, MSP, Confidentiality, Digital technology, ESOS, Health, Unicorn, Computer security, Growth, Multimedia, Business partner, L-1 Identity Solutions, Quadrant, Engineering, Managed services, HDS, Organization, Marketing, Information technology, Video game, Medical device, Risk management, Online shopping, Access, Member of the Scottish Parliament, Euronext

WALLIX is also adapting its Business Partner Program to target specific partners: IT and cloud service providers - MSPs (Managed Service Providers) which represent a growing market.

Key Points: 
  • WALLIX is also adapting its Business Partner Program to target specific partners: IT and cloud service providers - MSPs (Managed Service Providers) which represent a growing market.
  • On this occasion, WALLIX is also launching a program dedicated to IT and cloud service providers - the MSPs (Managed Service Providers).
  • WALLIX has strong expertise in this sector for many years and has just launched its OT.security by WALLIX brand.
  • IT and cloud service providers - MSPs (Managed Service Providers) - are an important area for WALLIX.

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Retrieved on: 
Monday, August 15, 2022
Janssen Pharmaceuticals, SIX, Allosteric regulation, Lists of diseases, Depression, Secondary research, Family, Glutamate (neurotransmitter), Drug discovery, CEO, Baclofen, Nasdaq, CHF, Psychosis, Clinical trial, Glutamate receptor, PAM, IND, American depositary receipt, SIX Swiss Exchange, Research, Pain, GABAB, Quality of life, GPCR, Therapy, Chronic cough, Spasticity, Epilepsy, Spinal cord injury, ADX71149, Additional funds needed, GABA, Protein, LR, NAM, Glutamic acid, LON, PAMS, Pharmaceutical industry, Indivior

As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx.

Key Points: 
  • As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, NYU Langone Health, Tachyphylaxis, Benzodiazepine, Biomarker, PAMS, US, Company, Vital signs, Epilepsy, Conference, Anxiety, PAM, Seizure, Engrailed (gene), Central nervous system, GABAergic, Disease, Half-life, Pain, Solution, Pharmacology, Patient, Somnolence, Restless, Acquisition, Safety, NYU, Clinical trial, Nervous system, GABA-A, ECG, Neurology, Quantitative electroencephalography, Baseline, Pharmaceutical industry, Vaccine, Health insurance

Engrail Therapeutics (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, has announced positive results from a phase 1b clinical trial of ENX-101, a subtype-selective GABA-A positive allosteric modulator (PAM).

Key Points: 
  • Engrail Therapeutics (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, has announced positive results from a phase 1b clinical trial of ENX-101, a subtype-selective GABA-A positive allosteric modulator (PAM).
  • The phase 1b clinical trial data were presented on June 6, 2022, at the 2022 Epilepsy Pipeline Conference in Santa Clara, California.
  • Following these results and recent interaction with the US FDA that included alignment on the phase 2 development program, Engrail plans to initiate the ENACT Trial, an international multi-center phase 2 clinical trial to evaluate the efficacy and safety of ENX-101 in patients with focal epilepsy.
  • There were no dose-related, clinically meaningful changes in vital signs, electrocardiograms, physical exams, or clinical laboratory values.

MACOM to Demonstrate RF and Microwave Amplifiers, Switches and Filters at IMS 2022

Retrieved on: 
Wednesday, June 1, 2022
Technology, Semiconductor, Security, Satellite, Photography, Telecommunications, Nanotechnology, Software, Audio, Video, VoIP, Networks, Internet, Mobile, Wireless, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, PAMS, RADAR, IMS, SATCOM, IEEE MTT-S International Microwave Symposium, Telecom, Analog, SOI, ISO14001, Data center, Defense, Solution, Filter bank, Microwave, Technology, RF, BAW, Optics, CW, ISO9001, Certification, Telecommunication, Aluminium gallium arsenide, Mobile phone, Electronic component, Industrial

MACOM Technology Solutions Inc. (MACOM), a leading supplier of semiconductor products, will demonstrate a wide range of new products at IEEEs International Microwave Symposium (IMS) in Denver, Colorado, June 21 23, 2022, Booth #6050.

Key Points: 
  • MACOM Technology Solutions Inc. (MACOM), a leading supplier of semiconductor products, will demonstrate a wide range of new products at IEEEs International Microwave Symposium (IMS) in Denver, Colorado, June 21 23, 2022, Booth #6050.
  • MACOM invites its customers to ask questions and interact with MACOM staff during the demonstrations.
  • IMS 2022 Product Demonstration Categories Include:
    AEROSPACE - MACOMs new, customizable RF Pallet designs using MACOM PURE CARBIDETM GaN amplifiers and integrated power management solutions.
  • MACOM services over 6,000 customers annually with a broad product portfolio that incorporates RF, Microwave, Analog and Mixed Signal and Optical semiconductor technologies.